Vir Biotechnology assembled its pipeline of infectious disease compounds through deal-making with other drug developers, along with financial support from blue-chip venture capital firms and the non-profit Bill & Melinda Gates Foundation. Now the biotech is turning to the public markets for the cash to continue clinical tests of its most advanced drug candidates.

San Francisco-based Vir set a preliminary $100 million target for its IPO, according to paperwork filed with securities regulators late Tuesday. Vir has applied for a Nasdaq listing under the stock symbol “VIR.”

Vir, founded in 2016, is developing drugs to treat and prevent infectious diseases in… Read more »